Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Since introduction of stapling instruments, which allow a safe hemostasis of hilar spleen vessels, the advantages of laparoscopic procedures are as well available for the laparoscopic splenectomy, like atraumatic dissection, reduced hospital stay, less bleeding and therefore less necessity of blood transfusion, and reduced analgetic consume. Laparoscopic splenectomy causes a lower morbidity comparing to open conventional splenectomy. Frequent indications for elective splenectomy are immune thrombocytopenic purpura, spherocytosis, Non Hodgkin Lymphoma and Hodgkin's disease. Limiting factors to laparoscopic splenectomy may be the size of spleen, concomiting diseases as portal hypertension and adhesions in upper left abdomen. To remove a big sized spleen we placed it within a large specimen retrival bag, which was partly delivered through a port in the left flank to allow digital morcellation of the spleen and piecemal removal. Eight females and fifteen males with a median age of 45 years (16-73) underwent splenectomy of immune thrombocytopenic purpura (14), spherocytosis (2), Non Hodgkin Lymphoma (5), Hodgkin's disease (1) and hair cell leukemia (1) with a spleen weight of 985 grams. The median operating time was 94 min (40-165) and median blood loss was 214 ml (50-400). Accessory spleens were removed in two cases. The median postoperative hospital stay was 5.6 days (3-10). The only complication was a parechymatous bleeding which needed conversion to open splenectomy. With careful selection of patients, laparoscopic splenectomy can be safely performed on normal and even enlarged spleens. The lateral approach is safe and offers excellent visualization of the splenic vessels, pancreas, and accessory spleens.
 ...
PMID:[Indications, technique and outcome of laparoscopic splenectomy]. 941 42

The association of immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) with Hodgkin's disease has been known for many years. Autoimmune cytopenia has also been described in patients that have undergone allogeneic or autologous bone marrow transplantation. We report a rare case of Evans syndrome in a patient 3 years after autologous bone marrow transplantation for recurrent Hodgkin's disease.
 ...
PMID:Evans syndrome after autologous bone marrow transplant for recurrent Hodgkin's disease. 946 85

Laparoscopic splenectomy remains a challenging procedure, as haemorrhage causes the most complications. In order to reduce this risk, preoperative selective embolisation of the splicing artery has been performed in a series of six successful laparoscopic splenectomies in one male and five female patients with a mean age of 34.6 years (range 17-53 yrs). Indications for surgery were immune thrombocytopenic purpura (ITP)(n = 3), non-Hodgkin lymphoma with secondary haemolytic anaemia (n = 1), autoimmune haemolytic anaemia (n = 1) and congenital spherocytosis (n = 1). The mean splenic length was 12.3 cm (range 9-16 cm) and no accessory spleens were identified. Mean operative time was 96.7 min (range 90-150 min). There were no deaths nor haemorrhagic or septic complications. Recovery after surgery was excellent with a mean hospital stay of 5.2 days (range 2-10 days). We conclude that selective embolisation of the splenic artery, just prior to laparoscopic splenectomy adds to the safety, and operating time may be shortened.
 ...
PMID:Laparoscopic splenectomy after arterial embolisation. 968 32

Infection by the human immunodeficiency virus (HIV) causes depletion of CD4-positive lymphocytes with consequent immunodeficiency. HIV infection also causes, by direct or indirect mechanisms, both reactive and neoplastic changes in lymphoid tissues. In primary infection reactive changes are a direct response to HIV. Later in the course of the disease there are reactive changes in lymph nodes and extranodal lymphoid tissues which are likely to be largely an indirect effect of HIV infection, being a response to opportunistic infection by other organisms. There is also an increased incidence of autoimmune phenomena in HIV-infected subjects which is likely to be consequent, at least in part, on impaired control of the proliferation of self-reactive B-cell clones. A second mechanism of immune damage of blood cells, probably operating in the case of HIV-related immune thrombocytopenic purpura, is that of cellular damage by immune complexes containing antiviral antibodies. Lymphoid neoplasms associated with HIV infection include non-Hodgkin's lymphoma, Hodgkin's disease and, uncommonly, plasma cell dyscrasias. HIV-associated lymphomas have distinct clinicopathological features and generally a poor prognosis. As for reactive lymphoid lesions, induction of neoplasia is likely, in the majority of cases, to be an indirect rather than a direct effect of the virus. The combination of chronic B-cell stimulation and impaired T-cell function is important, and interaction of lymphoid cells with virus-infected stromal cells may also play a role. Infection by oncogenic viruses such as the Epstein-Barr virus and human herpes virus 8 is also aetiologically important. In rare cases of T-cell lymphoma, HIV may be directly oncogenic.
 ...
PMID:Lymphomas and reactive lymphoid lesions in HIV infection. 974 85

Rituximab is a monoclonal chimeric antibody to the CD20 antigen, which has proven to be effective in the treatment of non-Hodgkin lymphomas. Recently, rituximab has also been employed in many non-malignant autoimmune disorders (i.e., idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, connective tissue disorders and autoimmune hemolytic anemia) in which it has been used with the aim of interfering with the production of pathologic antibodies. Moreover, this agent has also shown to be effective in the treatment of acquired antibodies against factor VIII. Through a careful literature search, the current knowledge on rituximab therapy in adult acquired hemophilia A is presented in this review. Although mostly based on uncontrolled studies, the literature data suggest that this drug can be useful in the treatment of disorders of acquired inhibitors to factor VIII. However, large, prospective, randomized trials are needed to confirm these positive preliminary results.
 ...
PMID:Rituximab in the treatment of adult acquired hemophilia A: a systematic review. 2650 21

Immunologic abnormalities have been described in patients with Hodgkin lymphoma, including autoimmune hemolytic anemia and immune thrombocytopenic purpura. The concurrent diagnoses of Hodgkin lymphoma and acquired aplastic anemia, however, is extremely rare. We report a 56-year-old Japanese female patient with severe aplastic anemia and increased large granular lymphocytes prior to the recurrence of Hodgkin lymphoma. After being in remission for 10 years from Hodgkin lymphoma, she developed progressive pancytopenia. The large granular lymphocytes (expressed CD3+ CD8+ TCRalphabeta+) had a polyclonal distribution, the serum-soluble FasL concentration was significantly elevated, and bone marrow biopsy showed severely hypocellular bone marrow without infiltration of abnormal lymphocytes. No lymphadenopathy was observed that would suggest a relapse of Hodgkin lymphoma. A diagnosis of aplastic anemia was made, and treatment with corticosteroids and cyclosporine was initiated. Two months later, she suddenly developed celiac and mediastinal lymphadenopathy. She underwent one cycle of chemotherapy before she died of progressive pancytopenia. Autopsy revealed the recurrence of Hodgkin lymphoma, nodular sclerosis in the lymph nodes and markedly hypocellular bone marrow. Although autoimmune disorders are described in Hodgkin lymphoma, our case shows a rare instance of a patient who had aplastic anemia as the first manifestation of a relapse of Hodgkin lymphoma.
 ...
PMID:Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes. 1731 50

Immunologic abnormalities have been described in patients with Hodgkin lymphoma, including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP). In this report, we describe a rare case of a 59-year-old woman who had autoimmune-mediated hepatitis and Hashimoto's thyroiditis at initial presentation of Hodgkin lymphoma. She was treated with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine), which induced a complete remission. One year later, she developed a sudden Coombs-positive hemolytic anemia and immune thrombocytopenia. She was diagnosed with Evans syndrome and was treated with prednisolone and intravenous immunoglobulin. However, the response of the therapies was poor; she died of progressive thrombocytopenia. The autopsy revealed the relapse of Hodgkin lymphoma of cervical lymph nodes. Although autoimmune disorders are described in Hodgkin lymphoma, our case shows a rare instance of a patient who had various immunologic abnormalities, including autoimmune-mediated hepatitis, Hashimoto's thyroiditis, AIHA, and ITP.
 ...
PMID:Hodgkin lymphoma presenting with various immunologic abnormalities, including autoimmune hepatitis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, and immune thrombocytopenia. 1850 Oct 91

Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-Hodgkin's B-cell lymphoma. Recently it has also been used in the treatment of several autoimmune diseases. A literature review was conducted to determine the efficacy of rituximab in the treatment of some of these autoimmune diseases. Multiple mechanisms proposed for the rituximab mediated B cell depletion are also discussed. The efficacy of rituximab is well-established and it is FDA approved for treatment of Rheumatoid arthritis. In this review, data on the use of rituximab is presented from 92 studies involving 1197 patients with the following diseases: systemic lupus erythematosus, idiopathic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody associated vasculitis, Grave's disease, autoimmune hemolytic anemia, pemphigus vulgaris, hemophilia A, cold agglutinin disease, Sjogren's syndrome, graft vs. host disease, thrombotic thrombocytopenic purpura, cryoglobulinemia, IgM mediated neuropathy, multiple sclerosis, neuromyelitis optica, idiopathic membranous nephropathy, dermatomyositis, and opsoclonus myoclonus. The efficacy varies among different autoimmune diseases. The cumulative data would suggest that in the vast majority of studies in this review, RTX has a beneficial role in their treatment. While rituximab is very effective in the depletion of B cells, current research suggests it may also influence other cells of the immune system by re-establishing immune homeostasis and tolerance. The safety profile of RTX reveals that most reactions are infusion related. In patients with autoimmune diseases the incidence of serious and severe side effects is low. Systemic infection still remains a major concern and may result in death.
 ...
PMID:A review of the current use of rituximab in autoimmune diseases. 1900 Jul 86

Hypothermia is an extremely rare clinical manifestation of unknown origin in Hodgkin disease, which is generally associated with the administration of chemotherapeutic agents. We present hypothermia in a 10-year-old girl with stage IIIB nodular sclerosing type Hodgkin disease, who was previously treated with the diagnosis of immune thrombocytopenic purpura. To the best of our knowledge, this case is the first reported case of hypothermia in Hodgkin disease with combination of previously treated immune thrombocytopenic purpura at childhood in the English medical literature.
 ...
PMID:Hypothermia in a child with Hodgkin disease. 1919 1

This article discusses the various hematologic and oncologic diseases to consider when caring for a patient with HIV infection. These diseases are not only more common in this patient population, but they can often be more severe, leading to greater morbidity and mortality than would be expected for a patient without HIV infection. Among the hematologic conditions discussed are common blood dyscrasias such as anemia, leucopenia, and thrombocytopenia, as well as less common disease processes such as immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and venous thromboses. The oncologic diseases discussed include AIDS-defining conditions, such as Kaposi sarcoma, invasive cervical carcinoma and non-Hodgkin lymphoma. The recognition of these conditions in patients infected with HIV is of paramount importance for identifying patients at high risk of morbidity and mortality.
 ...
PMID:Emergency department management of hematologic and oncologic complications in the patient infected with HIV. 2041 15


<< Previous 1 2 3 4 Next >>